ResearchMoz include new market research report"China Pharmaceutical Equipment Industry Report, 2013 - 2016: Industry Size, Shares, Growth, Trends And Forecast 2016" to its huge collection of research reports.

Albany, NY -- (SBWire) -- 02/13/2014 --After decades of development, China has become a major producer of pharmaceutical equipment in the world. Since 2010, affected by the new GMP certification and other factors, the revenue and total profit of China’s pharmaceutical equipment industry both have increased significantly, and the revenue achieved a year-on-year growth rate of 51.5%, 28.2% and 26% in 2010-2012 respectively.

However, restricted by the actual progress of new GMP certification and market capacity, the revenue growth of China’s pharmaceutical equipment industry will slow down in 2013-2016, probably at an annual average growth rate of 20% or so, and the revenue is expected to reach RMB 53.22 billion in 2016.

View Full Report With Complete TOC at http://www.researchmoz.us/china-pharmaceutical-equipment-industry-report-2013-2016-report.html

Due to a wide range of pharmaceutical equipment product categories and a customized business model generally adopted by enterprises, there is no one or a few pharmaceutical equipment companies capable of controlling the entire market, the industry concentration is low, the majority of enterprises are small and medium-sized, and the market concentration is low (20%?CR8<40%).

Shinva Medical Instrument Co., Ltd. is a leading sterilization equipment company in China. Its revenue from medical equipment (including pharmaceutical equipment) was RMB 2.408 billion in 2012 and RMB 1.524 billion in the first half of 2013. According to the statistics of China Association for Pharmaceutical Equipment, Shinva sold 10,048 units of sterilization equipment in 2012 and 7,873 units in the first 11 months of 2013, accounting for 86.8% and 84.3% of the total sales volume respectively.

Shanghai Tofflon Science and Technology Co., Ltd. is the leader in China’s freeze-drying system industry, and realized revenue of RMB 822 million in 2012, accounting for 3.3% of China’s pharmaceutical equipment market; in China’s freeze-dryer market, it occupied a market share of 50-60% by sales in 2012 and 2013.

Browse Other Published Reports By Research In China at http://www.researchmoz.us/publisher/research-in-china-67.html

Truking Technology Limited is a major supplier of liquid injection pharmaceutical equipment in China, its revenue in 2012 was RMB 589 million, occupying 2.3% of China’s pharmaceutical equipment market; in 2012, it accounted for 29.2% of the infusion device market by sales volume. Hunan China Sun Pharmaceutical Machinery Co., Ltd. is also an important supplier of injection pharmaceutical equipment in China, its revenue in 2012 was RMB 365 million, holding 1.4% of China’s pharmaceutical equipment market; in 2012, it contributed 19.1% of the sales volume in the infusion device market.

Related Reports -

Frontier Pharma: Systemic Lupus Erythematosus - Identifying and Commercializing First-in-Class Innovation

The Systemic Lupus Erythematosus (SLE) drug market is currently under-served by non-generic, targeted therapies. Whilst the only Food and Drug Administration (FDA)-approved biologic, Benlysta (belimumab), generated sales of $111m in 2012, there is little evidence that the drug’s performance is significantly superior to other B-cell targeted therapies such as Rituxan (rituximab), which is often used off-license to treat refractory SLE patients. Therapeutics entering the market therefore do not face the staggering level of competition from currently marketed programs as in other markets such as the Rheumatoid Arthritis (RA) market. Emerging market entrants that appear to offer significant therapeutic benefits are likely to cause dramatic changes to the market landscape.

View Full Report With Complete TOC at http://www.researchmoz.us/frontier-pharma-systemic-lupus-erythematosus-identifying-and-commercializing-first-in-class-innovation-report.html

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period.

View Full Report With Complete TOC at http://www.researchmoz.us/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth-report.html

Parkinsons Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management

Parkinson’s Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management”. The Parkinson’s Disease (PD) market is dominated by symptomatic treatments targeting functional impairment in PD. Levodopa has remained the gold standard treatment for almost 40 years and has significantly improved patient quality of life. There is currently there is a huge unmet need for disease-modifying treatments that slow progression or have neuroprotective properties. Over the 2012–2019 forecast period, the PD market is anticipated to decline from $3.4 billion in 2012 to $2.9 billion in 2019, as a consequence of upcoming patent expirations of high-profile products such as Azilect, Stalevo and Comtan. Although a few market entrants are anticipated to enter the market over the forecast period, they are not expected to offset the impact of generic erosion.

View Full Report With Complete TOC at http://www.researchmoz.us/parkinsons-disease-therapeutics-market-to-2019-pipeline-shows-shift-towards-long-term-disease-management-report.html

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

For More Information Kindly Contact:
Website@ http://www.researchmoz.us/
Email: sales@researchmoz.us

Browse Blog - http://pramoddige91.wordpress.com/